BeiGene Files China BLA for Sylvant, a Rare Disease Therapy

BeiGene and the UK 's EUSA Pharma announced that their Sylvant ® BLA was accepted for Priority Review in China . Sylvant is a treatment for adult patients with multicentric Castleman’s disease (MCD). A rare disease, MCD is a debilitating condition of the lymph nodes and related tissues. One year ago, BeiGene acquired Greater China commercialization rights to Sylvant from EUSA as part of a $160 million two-drug in-licensing agreement. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //